Top Story Today
Pfizer Crashes the Obesity Party With a $10 Billion Ticket
Pfizer is acquiring Metsera, a three-year-old biotech with no approved drugs, for up to $10 billion in cash. Metsera's pipeline centers on once-monthly GLP-1 injections for obesity, and the deal's structure tells the real story: only $65.60 per share lands at closing, with another $20.65 per share tied to Phase 3 initiation and FDA approvals. One analyst estimates Metsera's drugs would need to generate $11 billion in revenue by 2040 just to earn Pfizer a return. With Novo Nordisk and Eli Lilly already dominating the obesity market, Pfizer is paying a steep cover charge to a party that started without it.
Why it matters: This is Pfizer's clearest admission yet that its internal obesity efforts failed, and it signals a broader industry truth: any company without a GLP-1 franchise is now willing to pay a massive premium to buy one. The deal reshapes the obesity competitive landscape heading into 2027.
Read more →Deals and Partnerships
Novartis Buys a Key to the Brain's Front Door for $125M
Most biologic drugs can't cross the blood-brain barrier, which is a massive problem for treating Alzheimer's, ALS, and Huntington's. Novartis paid $125 million to acquire Sironax's Brain Delivery Module platform, which engineers drugs to hitch a ride on the brain's natural transport receptors. It's the latest in a quiet three-year shopping spree that reveals Novartis is assembling a full toolkit for brain-penetrant biologics.
Read more →Roche Bets Up to $1B on a Machine That Tests 300,000 Antibody Combos
Three-year-old Dualitas Therapeutics just landed a deal worth up to $1 billion from Roche, with $36.5 million upfront. Dualitas's DualScreen platform can functionally test over 300,000 bispecific antibody combinations at once, flipping the traditional approach: screen everything first, then figure out what works. Roche wants it for immunology and inflammation.
Read more →Novo Nordisk Adds Anthropic to Its Growing AI Roster
The world's most valuable pharma company partnered with Anthropic to deploy Claude AI across drug discovery, stacking it alongside existing deals with OpenAI and NVIDIA. Novo wants to be "the most AI-driven healthcare company," and the broader industry is sprinting behind it: Merck, Pfizer, and AstraZeneca have all inked their own nine- and ten-figure AI partnerships.
Read more →Lilly Plugs Twist Bioscience Into Its AI Drug Discovery Flywheel
Eli Lilly connected Twist Bioscience's antibody libraries (over 15 collections, each with up to ten billion candidates) to its TuneLab AI platform. No splashy price tag here; the real play is a data flywheel where every experiment makes the AI smarter. Lilly is pairing this with an NVIDIA supercomputer and up to $1 billion in compute infrastructure.
Read more →Clinical Trials and Data
A Cancer Drug's Mirror Image Just Posted JAK-Like Arthritis Results
AnaptysBio's rosnilimab does the opposite of Keytruda: it activates PD-1 to calm the immune system instead of unleashing it. In a 424-patient Phase 2b trial, it matched JAK inhibitor-level efficacy in rheumatoid arthritis, with responses deepening through six months. The kicker: it uses an entirely different mechanism, potentially sidestepping JAK inhibitors' boxed warning for cardiovascular risk.
Read more →Huntington's Patients Actually Improved on Skyhawk's Oral Pill
In a disease where patients only decline, Skyhawk's SKY-0515 showed functional improvement over 15 months, opening a 1.59-point gap versus untreated patients (p<0.001). Unlike prior Huntington's failures that required spinal injections, this one's a pill. The catch: data came from an open-label study with external controls, so the randomized Phase 2/3 trial will be the real proving ground.
Read more →First Human Dosed With an Oral Drug Targeting ALS's Most Common Culprit
Acelot dosed the first healthy volunteer with ACE-2223, an oral pill designed to break up toxic TDP-43 protein clumps found in 97% of sporadic ALS cases. No approved therapy targets this protein directly. The Phase Ia trial is testing safety first; ALS patients come later. In mice, the drug reduced aggregation and improved survival.
Read more →Funding and Approvals
Sling Raises $123M to Replace a $2 Billion Needle With a Pill
Thyroid eye disease patients currently need eight IV infusions of Amgen's Tepezza (which pulled in $1.9 billion last year). Sling Therapeutics raised $123 million to fund a Phase 3 trial for linsitinib, a twice-daily oral pill that hit its primary endpoint in Phase 2: 52% of patients saw meaningful eye improvement. The money funds a global pivotal trial called ORBIT.
Read more →First New Kidney Drug for Type 1 Diabetes in Years
The FDA granted Priority Review to Bayer's Kerendia for chronic kidney disease in Type 1 diabetes, a population of roughly 258,000 Americans with limited treatment options. Trial data showed a 25% reduction in kidney damage markers versus placebo. Kerendia brought in nearly $1 billion in 2025 sales across its existing indications.
Read more →